<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>27(3)</volume><submitter>Johns E</submitter><funding>Princess Alexandra Hospital Research Foundation</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Brain metastases (BM) occur in at least 20% of people with an advanced solid malignancy and can lead to morbidity or mortality if not controlled. Hypofractionated stereotactic radiotherapy (HF-SRT) may be preferred to single fraction stereotactic radiosurgery (SRS) in certain clinical situations to improve the therapeutic ratio. Certain dose-volume metrics can predict the risk of symptomatic radionecrosis or other toxicities after HF-SRT but dosimetric predictors of more complex outcomes such as cognitive function are less well described. For this reason, clinicians aim to limit the dose to uninvolved brain so that it is as low as reasonably achievable rather than simply aiming for a threshold goal. The number of treatment arcs and arc length, floor angles and volumetric</pubmed_abstract><journal>Journal of applied clinical medical physics</journal><pagination>e70468</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12928994</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Modeling dose to normal brain following hypofractionated stereotactic radiotherapy to a single brain metastasis.</pubmed_title><pmcid>PMC12928994</pmcid><pubmed_authors>Pinkham MB</pubmed_authors><pubmed_authors>Bernard A</pubmed_authors><pubmed_authors>Johns E</pubmed_authors><pubmed_authors>Hargrave C</pubmed_authors><pubmed_authors>Nissen L</pubmed_authors><pubmed_authors>Barry TJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Modeling dose to normal brain following hypofractionated stereotactic radiotherapy to a single brain metastasis.</name><description>&lt;h4>Background&lt;/h4>Brain metastases (BM) occur in at least 20% of people with an advanced solid malignancy and can lead to morbidity or mortality if not controlled. Hypofractionated stereotactic radiotherapy (HF-SRT) may be preferred to single fraction stereotactic radiosurgery (SRS) in certain clinical situations to improve the therapeutic ratio. Certain dose-volume metrics can predict the risk of symptomatic radionecrosis or other toxicities after HF-SRT but dosimetric predictors of more complex outcomes such as cognitive function are less well described. For this reason, clinicians aim to limit the dose to uninvolved brain so that it is as low as reasonably achievable rather than simply aiming for a threshold goal. The number of treatment arcs and arc length, floor angles and volumetric</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Mar</publication><modification>2026-07-16T20:26:13.384Z</modification><creation>2026-07-10T03:10:39.248Z</creation></dates><accession>S-EPMC12928994</accession><cross_references><pubmed>41730691</pubmed><doi>10.1002/acm2.70468</doi></cross_references></HashMap>